JP2021535211A5 - - Google Patents
Info
- Publication number
- JP2021535211A5 JP2021535211A5 JP2021534820A JP2021534820A JP2021535211A5 JP 2021535211 A5 JP2021535211 A5 JP 2021535211A5 JP 2021534820 A JP2021534820 A JP 2021534820A JP 2021534820 A JP2021534820 A JP 2021534820A JP 2021535211 A5 JP2021535211 A5 JP 2021535211A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- fragment
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024016700A JP7835788B2 (ja) | 2018-08-21 | 2024-02-06 | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
| GB1813597.0 | 2018-08-21 | ||
| GB1900983.6 | 2019-01-24 | ||
| GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
| PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016700A Division JP7835788B2 (ja) | 2018-08-21 | 2024-02-06 | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535211A JP2021535211A (ja) | 2021-12-16 |
| JP2021535211A5 true JP2021535211A5 (enExample) | 2022-08-29 |
| JP7434328B2 JP7434328B2 (ja) | 2024-02-20 |
Family
ID=67688785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534820A Active JP7434328B2 (ja) | 2018-08-21 | 2019-08-20 | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 |
| JP2024016700A Active JP7835788B2 (ja) | 2018-08-21 | 2024-02-06 | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024016700A Active JP7835788B2 (ja) | 2018-08-21 | 2024-02-06 | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20210395350A1 (enExample) |
| EP (2) | EP4659807A3 (enExample) |
| JP (2) | JP7434328B2 (enExample) |
| KR (2) | KR20250148711A (enExample) |
| CN (2) | CN112930356B (enExample) |
| AU (3) | AU2019326740B2 (enExample) |
| CA (1) | CA3110013A1 (enExample) |
| DK (1) | DK3841120T3 (enExample) |
| ES (1) | ES3048210T3 (enExample) |
| FI (1) | FI3841120T3 (enExample) |
| HR (1) | HRP20251346T1 (enExample) |
| IL (2) | IL322482A (enExample) |
| LT (1) | LT3841120T (enExample) |
| MX (3) | MX2025007881A (enExample) |
| PT (1) | PT3841120T (enExample) |
| RS (1) | RS67385B1 (enExample) |
| SG (1) | SG11202101652PA (enExample) |
| SI (1) | SI3841120T1 (enExample) |
| SM (1) | SMT202500388T1 (enExample) |
| WO (1) | WO2020038963A1 (enExample) |
| ZA (1) | ZA202101051B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| CN112930356B (zh) | 2018-08-21 | 2025-03-21 | 奇特里尔私人有限公司 | 与瓜氨酸化的组蛋白2a和/或4结合的抗体 |
| WO2020072993A1 (en) | 2018-10-05 | 2020-04-09 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
| WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
| JP2023533504A (ja) * | 2020-07-07 | 2023-08-03 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムの処置および予防のための併用療法 |
| GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5364870B2 (ja) | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| CN102056944A (zh) | 2008-06-04 | 2011-05-11 | 莫蒂克斯特私人有限公司 | 抗炎症药剂 |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
| JP7037940B2 (ja) | 2014-12-11 | 2022-03-17 | シトリル べー．フェー． | 特発性肺線維症の治療方法 |
| WO2017021552A1 (en) | 2015-08-06 | 2017-02-09 | Novimmune Sa | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| CN112930356B (zh) | 2018-08-21 | 2025-03-21 | 奇特里尔私人有限公司 | 与瓜氨酸化的组蛋白2a和/或4结合的抗体 |
| CN117396221A (zh) * | 2021-05-04 | 2024-01-12 | 奇特里尔私人有限公司 | 嗜酸性粒细胞陷阱的抑制 |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
-
2019
- 2019-08-20 CN CN201980070130.3A patent/CN112930356B/zh active Active
- 2019-08-20 EP EP25196231.2A patent/EP4659807A3/en active Pending
- 2019-08-20 RS RS20251114A patent/RS67385B1/sr unknown
- 2019-08-20 MX MX2025007881A patent/MX2025007881A/es unknown
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/es unknown
- 2019-08-20 HR HRP20251346TT patent/HRP20251346T1/hr unknown
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en not_active Ceased
- 2019-08-20 SM SM20250388T patent/SMT202500388T1/it unknown
- 2019-08-20 FI FIEP19756180.6T patent/FI3841120T3/fi active
- 2019-08-20 CN CN202510240710.XA patent/CN120058926A/zh active Pending
- 2019-08-20 ES ES19756180T patent/ES3048210T3/es active Active
- 2019-08-20 PT PT197561806T patent/PT3841120T/pt unknown
- 2019-08-20 AU AU2019326740A patent/AU2019326740B2/en active Active
- 2019-08-20 KR KR1020257029356A patent/KR20250148711A/ko active Pending
- 2019-08-20 KR KR1020217008362A patent/KR102871821B1/ko active Active
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 IL IL322482A patent/IL322482A/en unknown
- 2019-08-20 IL IL280995A patent/IL280995B2/en unknown
- 2019-08-20 DK DK19756180.6T patent/DK3841120T3/da active
- 2019-08-20 LT LTEPPCT/EP2019/072302T patent/LT3841120T/lt unknown
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 SI SI201930975T patent/SI3841120T1/sl unknown
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/ja active Active
- 2019-08-20 EP EP19756180.6A patent/EP3841120B1/en active Active
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-17 MX MX2025007882A patent/MX2025007882A/es unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US12590143B2/en active Active
-
2024
- 2024-02-06 JP JP2024016700A patent/JP7835788B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201303A patent/AU2026201303A1/en active Pending
- 2026-02-20 AU AU2026201302A patent/AU2026201302A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220267476A1 (en) | Multispecific antibody constructs | |
| HRP20251346T1 (hr) | Antitijela koja se vezuju za citrulirani histon 2a i/ili 4 | |
| CN108473563B (zh) | 改进的tnf结合剂 | |
| CN101578298A (zh) | 结合il-4和/或il-13的配体 | |
| JP2021513974A5 (enExample) | ||
| CN104105708A (zh) | PDGF受体β结合多肽 | |
| IL291571B2 (en) | Cx3cr1-binding polypeptides | |
| US11365240B2 (en) | Anti-HSA antibodies | |
| CN115433284A (zh) | 一种针对转铁蛋白受体1的纳米抗体及其应用 | |
| JP2021530244A5 (enExample) | ||
| JP2022512647A5 (enExample) | ||
| JP2023508674A5 (enExample) | ||
| JP2026048732A5 (enExample) | ||
| WO2021113740A1 (en) | Compositions and methods for reducing off-target toxicity of antibody drug conjugates | |
| CN111808193A (zh) | 可结合人cd38的纳米抗体及其应用 | |
| CN116162160A (zh) | 一种抗il-6的单域抗体及其用途 | |
| JP2026071342A (ja) | 抗ＩｇＥ改変抗体及びその適用 | |
| JP2024523514A5 (enExample) | ||
| CN116284408A (zh) | 结合人muc17的抗体、其制备方法及用途 | |
| TW202415677A (zh) | 抗TNFα抗體及組合物 | |
| CN117843783A (zh) | 抗人cd70抗体及其应用 | |
| CN116162161A (zh) | 一种抗il-6r的单域抗体及其用途 | |
| WO2021190500A1 (zh) | SARS-CoV-2和SARS-CoV交叉中和抗体的制备及应用 | |
| HK40105696A (zh) | 新的间皮素抗体和包含其的组合物 | |
| TW202608916A (zh) | 白蛋白結合蛋白及使用方法 |